MGMT testing for glioma in clinical laboratories: discordance with methylation analyses prevents the implementation of routine immunohistochemistry.
about
Prognostic and predictive markers in recurrent high grade glioma; results from the BR12 randomised trialAssessment of Quantitative and Allelic MGMT Methylation Patterns as a Prognostic Marker in GlioblastomaEmerging biomarkers in glioblastomaThe Diagnostic Use of Immunohistochemical Surrogates for Signature Molecular Genetic Alterations in Gliomas.O(6)-methylguanine-DNA methyltransferase activity is associated with response to alkylating agent therapy and with MGMT promoter methylation in glioblastoma and anaplastic glioma.Molecular profiling of short-term and long-term surviving patients identifies CD34 mRNA level as prognostic for glioblastoma survival.
P2860
MGMT testing for glioma in clinical laboratories: discordance with methylation analyses prevents the implementation of routine immunohistochemistry.
description
article científic
@ca
article scientifique
@fr
articol științific
@ro
articolo scientifico
@it
artigo científico
@gl
artigo científico
@pt
artigo científico
@pt-br
artikel ilmiah
@id
artikull shkencor
@sq
artículo científico
@es
name
MGMT testing for glioma in cli ...... routine immunohistochemistry.
@en
type
label
MGMT testing for glioma in cli ...... routine immunohistochemistry.
@en
prefLabel
MGMT testing for glioma in cli ...... routine immunohistochemistry.
@en
P2860
P1476
MGMT testing for glioma in cli ...... routine immunohistochemistry.
@en
P2093
Kerrie McDonald
Sofia Mason
P2860
P2888
P304
P356
10.1007/S00432-012-1312-1
P577
2012-09-18T00:00:00Z